This Week in Dermatology — Jun 27, 2026

Welcome to This Week in Dermatology. This week we're covering 9 notable papers spanning atopic dermatitis prevention and management, the systemic and behavioral burdens of chronic inflammatory skin diseases, and new insights into cutaneous biology and onco-dermatology. Let's dive in.

We begin this week with a focus on atopic dermatitis, looking first at how early-life interventions might prevent its onset, followed by modern delivery models and systemic treatment trajectories. Frequent infant bathing, even in plain tap water, is known to alter skin physiology and has been hypothesized to increase the risk of developing eczema. To address this, a randomized controlled feasibility trial published in The British Journal of Dermatology evaluated a behavioral intervention aimed at reducing infant bathing frequency and intensity [6]. The study enrolled 105 pregnant women with a family history of atopy who were carrying a healthy singleton child. Parents in the intervention arm were instructed to bathe their infants no more than once a week for the first six months of life, keeping the baths short, not too hot, and using plain water. Adherence to this protocol was remarkably high, with nearly eighty percent of the intervention group bathing their infants once a week or less, compared to only about twenty-nine percent of the control group, who received routine postnatal care advice. At six months of age, a blinded assessment revealed that visible eczema occurred in fifteen point eight percent of the intervention group compared to twenty-nine point two percent of the control group, which represents a substantial reduction. Parent-reported eczema and doctor-diagnosed parent-reported eczema also trended lower in the reduced-bathing group. With no noteworthy adverse effects reported and high parental acceptability, these findings suggest that a simple, low-cost recommendation to limit infant bathing is highly feasible and could serve as an effective early preventive strategy for families with a history of allergic disease.

For patients who do develop atopic dermatitis, optimizing healthcare delivery and treatment strategies is essential for maintaining quality of life. In a twelve-month, pragmatic, randomized equivalence trial published in The Journal of Investigative Dermatology, researchers evaluated whether an online, team-based connected health teledermatology model could deliver outcomes equivalent to traditional in-person management [5]. The trial randomized 300 participants aged one year or older with physician-diagnosed atopic dermatitis to either online or in-person care. The results demonstrated that the online model achieved equivalent improvements in quality of life, as measured by the Dermatology Life Quality Index and the EQ-5D-5L utility index, with all differences falling well within the prespecified equivalence margins. Furthermore, the online model significantly reduced the average time required for clinical evaluation at baseline, highlighting teledermatology as a highly efficient and equivalent alternative to standard in-person visits. Meanwhile, for patients with moderate-to-severe disease requiring advanced systemic therapy, real-world data on oral Janus kinase 1 inhibitors like abrocitinib are increasingly vital. A retrospective landmark analysis published in Clinical and Experimental Dermatology evaluated treatment trajectories and dose optimization of abrocitinib in fifty-eight adult patients [8]. At baseline, thirty-seven patients initiated the two-hundred-milligram dose, while twenty-one started on the one-hundred-milligram dose. By week sixteen, the vast majority of patients maintained their starting dose. However, about twenty-four percent of those on the lower dose required escalation to two hundred milligrams due to insufficient efficacy, while approximately eleven percent of those on the higher dose stepped down to one hundred milligrams because of tolerability concerns or clinical improvement. Clinically meaningful reductions in disease severity, pruritus, and quality of life scores were observed across all trajectories, with no significant differences in outcomes at week twenty-four, indicating that real-world dose optimization can be tailored to individual patient needs without compromising short-term control.

Next, we turn to the systemic nature of chronic inflammatory skin diseases, starting with hidradenitis suppurativa. While often conceptualized as a localized disease of the intertriginous skin, a proteomic analysis published in the Journal of the European Academy of Dermatology and Venereology underscores the presence of systemic inflammation across all clinical stages [1]. Researchers utilized a specialized inflammation panel to quantify ninety-two immune-related proteins in the serum of forty-four patients with hidradenitis suppurativa and forty-four age- and sex-matched healthy controls. The analysis identified thirty-seven inflammatory proteins that were significantly different between the two groups. Notably, key inflammatory mediators such as tumor growth factor-alpha, oncostatin M, interleukin-8, interleukin-7, ligand for receptor TNFRSF14, and hepatocyte growth factor were elevated even in patients with mild, Hurley stage one disease. Other markers, including interleukin-6, interleukin-17A, and vascular endothelial growth factor A, increased progressively with worsening Hurley stages. Interleukin-6 and hepatocyte growth factor levels correlated directly with disease severity and quality of life impairment, while interleukin-17A was associated with a longer duration of disease. These findings reinforce the understanding of hidradenitis suppurativa as a systemic inflammatory condition from its earliest onset, suggesting that early, comprehensive systemic management may be necessary to prevent long-term tissue damage and systemic comorbidities.

The systemic burden of these chronic inflammatory skin diseases is not limited to circulating cytokines; it also manifests as a high prevalence of mental health and behavioral comorbidities, particularly addictive behaviors. A systematic review of thirty-eight studies published in the Journal of the European Academy of Dermatology and Venereology investigated the prevalence and clinical impact of substance-related and behavioral addictions in adults with conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa [2]. The review revealed a striking burden of addictive behaviors, with alcohol addiction prevalence reaching up to fifty percent and nicotine abuse affecting up to forty percent of patients. Furthermore, behavioral addictions, such as internet addiction, were reported in up to thirty-eight percent of cases. The presence of these addictions was consistently associated with greater skin disease severity, reduced response to dermatological treatments, and a higher overall comorbidity burden. These findings highlight a critical gap in current clinical practice, suggesting that dermatologists should systematically screen for both substance-related and underrecognized behavioral addictions to provide holistic, multidisciplinary care that can improve both dermatological and psychiatric outcomes.

Our third theme explores the cellular and immunological defense mechanisms of the skin, as well as localized cutaneous reactions. In a study published in The Journal of Investigative Dermatology, researchers investigated how the skin coordinates its early innate defenses against Candida auris, an emerging multidrug-resistant fungal pathogen known for its ability to persist on human skin [3]. Using ex vivo human skin models along with primary keratinocytes and fibroblasts, the authors demonstrated that Candida auris forms biofilms and triggers a pro-inflammatory response characterized by the secretion of interleukin-1-beta and interleukin-6, while causing minimal direct epithelial damage. The study revealed that keratinocytes act as critical sentinel cells, upregulating antimicrobial peptides such as RNase 7, thymic stromal lymphopoietin, and human beta-defensin 3, alongside neutrophil-recruiting chemokines. Fibroblasts, in turn, amplify the inflammatory response and secrete chemokines that support T-cell recruitment and tissue remodeling. Crucially, recombinant RNase 7 and thymic stromal lymphopoietin directly inhibited the growth of Candida auris in vitro, suggesting that enhancing these endogenous antimicrobial peptides within the skin barrier could offer a novel therapeutic avenue to limit colonization and prevent nosocomial transmission.

Understanding how the skin's cellular landscape responds to environmental stressors is also key to preventing long-term malignancies. Another study in The Journal of Investigative Dermatology utilized single-nucleus RNA sequencing of frozen tissue to analyze how human melanocytic nevi respond in vivo to simulated solar radiation [4]. By profiling single nuclei from frozen specimens without prior cell enrichment, the researchers mapped the transcriptional changes across diverse cell populations, including melanocytes, keratinocytes, fibroblasts, and immune cells. The study successfully mapped the distinct gene expression profiles of interfollicular basilar melanocytes versus nevomelanocytes, highlighting pathways involved in cellular senescence. Following exposure to simulated solar radiation, the researchers identified significant transcriptional changes in gene modules containing SERPINE2 as well as components of the insulin-like growth factor 1 signaling axis in nevus cells, fibroblasts, and endothelial cells. These findings, which were validated using tissue-based RNAscope analysis, provide highly specific molecular targets and biomarkers that could be utilized in future clinical trials evaluating melanoma prevention agents.

While physical and biological stressors shape long-term cutaneous health, acute drug reactions present immediate diagnostic challenges. A systematic review published in Clinical and Experimental Dermatology synthesized data from seventy studies involving two hundred and sixty-two male patients to characterize the clinical and etiological features of male genital fixed drug eruptions [7]. Genital involvement is a frequent mucosal site for fixed drug eruptions but is often misdiagnosed as a sexually transmitted infection. The review found that the median age of presentation was thirty-five point five years, with lesions predominantly localized to the glans penis in nearly seventy-three percent of cases, followed by the penile shaft and foreskin. Erythema was the most common presentation, followed by erosions and bullae, with the eruption being entirely isolated to the genitalia in seventy-nine percent of patients. A specific causative drug was identified in over ninety-three percent of cases, with the most common triggers being trimethoprim-sulfamethoxazole, cyclines, and non-steroidal anti-inflammatory drugs. The median time to lesion onset after drug exposure was forty-eight hours. Recognizing these characteristic clinical patterns and common drug triggers is essential for clinicians to make an accurate diagnosis, avoid unnecessary diagnostic testing for sexually transmitted infections, and prevent recurrent episodes through patient education and drug avoidance.

Finally, bridging the gap between systemic medicine and cutaneous oncology, a study published in Nature Medicine identified plasma metabolic predictors of response to immune-checkpoint inhibitors in patients with advanced cancers [9]. By profiling over four thousand plasma samples from more than seventeen hundred patients across five different tumor types, researchers developed a machine-learning model integrating clinical variables with one hundred and fifty-four metabolites. The model successfully predicted twelve-month progression-free survival in both training and external validation cohorts. Specifically, high levels of the amino acid histidine were identified as a favorable prognostic marker for survival, whereas elevated long-chain fatty acids and succinate were associated with poorer outcomes. In animal models, histidine supplementation enhanced antitumor immunity, and in clinical cohorts, histidine-rich diets improved progression-free survival, particularly in patients who lacked gut microbiota signatures associated with histidine degradation. This highlights the potential of integrating metabolic and metagenomic profiling to personalize cancer immunotherapy.

If you only have time for one paper this week, make it the randomized controlled feasibility trial of infant bathing reduction from The British Journal of Dermatology [6]. This work offers a simple, highly acceptable, and low-cost behavioral intervention during infancy that could fundamentally alter the trajectory of atopic dermatitis development in high-risk families.

Here are the key takeaways from this week in Dermatology: First, advising parents of high-risk infants to limit bathing to once a week or less using plain water is a highly feasible strategy that may substantially lower early eczema rates [6]. Second, online, team-based teledermatology models for atopic dermatitis provide equivalent improvements in quality of life compared to traditional in-person care while significantly speeding up baseline evaluations [5]. Third, hidradenitis suppurativa drives systemic inflammatory protein elevation even in its mildest stages, reinforcing the need for early, aggressive intervention rather than waiting for advanced structural damage [1]. Fourth, clinicians should routinely screen patients with chronic inflammatory skin diseases for alcohol, nicotine, and behavioral addictions, as these are highly prevalent and linked to poorer treatment responses [2]. And finally, when evaluating suspected male genital lesions, keep fixed drug eruption high on your differential, particularly on the glans penis, and ask about recent exposure to trimethoprim-sulfamethoxazole, cyclines, or non-steroidal anti-inflammatory drugs [7].

That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.